AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02411903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin and clopidogrel
Description: Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
Study NCT03769922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive mesenteric resection
Description: The mesentery is resected avoiding the root region.
Study NCT03769922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limited mesenteric excision
Description: The mesentery is retained.
Study NCT03327545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.
Study NCT03327545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft tissue techniques and Stretching
Description: Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes
Study NCT03327545 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Did not receive any treatment.
Study NCT03067103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
Study NCT02602067 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 131I-Tenatumomab
Description: I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
Study NCT00609141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV
Study NCT00609141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00609141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02493868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
Study NCT02493868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
Study NCT01209338 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Health education
Description: Health education about HPV infection, HPV vaccine and cervix cancer.
Study NCT01209338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education about HPV infection, HPV vaccine and cervix cancer.
Study NCT02254096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 1696 BS
Study NCT02254096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02254096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Study NCT02254096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal (HFM)
Study NCT02493868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study NCT02493868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram (Oral antidepressant)
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
Study NCT05409274 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT02493868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
Study NCT02493868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
Study NCT00147498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at a dose of 5 mg BID for 6 weeks
Study NCT00147498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at a dose of 15 mg BID for 6 weeks
Study NCT00147498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 30 mg BID for 6 weeks
Study NCT00147498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT04074655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Driving Simulator in a Virtual Reality Environment
Description: Driving simulator in virtual reality environment is a game with the several level of difficulty and the goal of improving the cognition level of participants in general and their spatial cognition in particular. Moreover this game, will have a positive effect on its users' mood as well.
Study NCT02447874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours
Study NCT02447874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine (Loading)
Description: Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
Study NCT02447874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine (Continuous)
Description: Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
Study NCT02152163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ibuprofen
Study NCT02152163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03129373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryogenic treatment of warts
Description: Treatment of common and plantar wart by cryotherapy treatment.
Study NCT03129373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryogenic treatment of warts
Description: Treatment of common and plantar wart by cryotherapy treatment.
Study NCT01065610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01065610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05191550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality brain tumor simulation
Description: Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks.
Study NCT00392665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given intravenously on day one of each 3 week cycle
Study NCT00392665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: Given orally once a day
Study NCT00392665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac
Description: Given orally twice a day
Study NCT00901745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
Study NCT00901745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
Study NCT00901745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion
Description: Infusion of up to 480 picomol/ml of noradrenaline will be infused.
Study NCT00901745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline infusion
Description: Infusion of up to 480 picomol/ml of noradrenaline will be infused.
Study NCT04364321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam 0.5 MG
Description: Clonazepam 0.02 mg/kg only one dose
Study NCT04364321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Tablets
Description: Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
Study NCT02259244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight reduction program
Study NCT02259244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight reduction program
Study NCT01725958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement and protein shakes
Study NCT01133470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine HCl + Pseudoephedrine HCl
Description: Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
Study NCT01133470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl + Pseudoephedrine HCl
Description: Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
Study NCT04215822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
Description: Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
Study NCT00789230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary suture closure
Description: primary suture closure of hernia
Study NCT00789230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mesh enforced closure
Description: mesh enforced closure of hernia
Study NCT02195193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
Study NCT01174225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexi T 380(+) IUD
Description: The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
Study NCT01174225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nova T IUD
Description: The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
Study NCT02477202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena® intra-uterine device (IUD)
Description: In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
Study NCT01648582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT01648582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Administered SC per dosing titration schedule
Study NCT01648582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Study NCT01648582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Study NCT01648582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Study NCT01648582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylureas
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Study NCT04460430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib + endocrine therapy
Description: Neratinib plus Fulvestrant, Exemestane or Tamoxifen
Study NCT01225354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite
Description: Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
Study NCT00326820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate sodium
Study NCT00326820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Study NCT00326820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolendronic Acid
Description: Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
Study NCT04222985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 1
Description: Route of administration: Intramuscular
Study NCT04222985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 2
Description: Route of administration: Intramuscular
Study NCT04222985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 3
Description: Route of administration: Intramuscular
Study NCT04222985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 4
Description: Route of administration: Intramuscular
Study NCT04222985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 5
Description: Route of administration: Intramuscular
Study NCT01092156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education on Infant-led latching
Study NCT05778539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral retinacular release
Description: During the implantation of a total knee arthroplasty a lateral retinacular release is performed in the intervention group
Study NCT03097263 — intervention group
Intervention type: OTHER
Intervention: Physical Rehabilitation program
Study NCT02540304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing the Risk
Description: Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
Study NCT02452411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.
Description: The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
Study NCT01042665 — intervention group
Intervention type: DRUG
Intervention: latanoprost 0.005%
Description: Active comparator
Study NCT01042665 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Placebo comparator
Study NCT00882505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Subject will receive vitamin d supplements
Study NCT00882505 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive a placebo.
Study NCT04546334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)
Study NCT04546334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Erector Spinae block
Description: Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose)
Study NCT04546334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Erector Spinae block with magnesium sulphate
Description: Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))
Study NCT04546334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Erector Spinae block
Description: Ultrasound guided Erector spinae plane block with injection ofnormal saline
Study NCT02404701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe vera with cactus
Description: Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.